Page last updated: 2024-08-25

bexarotene and Skin Neoplasms

bexarotene has been researched along with Skin Neoplasms in 169 studies

Research

Studies (169)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	85 (50.30)	29.6817
2010's	53 (31.36)	24.3611
2020's	31 (18.34)	2.80

Authors

Authors	Studies
Athar, M; Atigadda, VR; Belyaeva, OV; Chang, PL; Chattopadhyay, D; Chou, CF; Elmets, CA; Grubbs, CJ; Kashyap, MP; Kedishvili, NY; Melo, N; Muccio, DD; Renfrow, MB; Sinha, R; Yang, Z	1
Ahmadu, C; Armstrong, N; Chalker, A; Duffy, S; Grimm, SE; Hiligsmann, M; Joore, MA; Kleijnen, J; Ryder, S; Syndikus, I; Wijnen, B; Witlox, W; Wolff, R	1
Eich, HT; Elsayad, K; Livingstone, E; Moritz, RKC; Müller, EC; Nawar, T; Rolf, D; Stadler, R; Steinbrink, K; Stranzenbach, R; Sunderkötter, C; Weishaupt, C	1
Demirci Saadet, E; Kalay Yildizhan, I; Okcu Heper, A; Sanli, H	1
Bayramgürler, D; Demirbaş, A; Demirkesen, C; Eruyar, T; Kazan, D	1
Ginsburg, E; Hennessy, K; Mhaskar, R; Seminario-Vidal, L	1
D'Incan, M; Joulie, I; Lambert, C; Rouanet, J	1
Hongying, P; Kobayashi, T; Kojima, K; Mitsuhashi, A; Nishikimi, K; Shioya, M; Shozu, M; Yahiro, K	1
Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N	1
Aquino, C; Avallone, G; Boskovic, S; Fava, P; Macagno, N; Quaglino, P; Ribero, S; Roccuzzo, G	1
Asano, Y; Fujimura, T; Hashimoto, A; Kambayashi, Y; Tamabuchi, E; Yamamoto, H	1
Ardigò, M; Cicini, MP; Franceschini, C; Mandel, VD; Saraceni, PL; Teoli, M	1
di Martino, O; Ivan, DJ; Jurutka, PW; Khadka, I; Krall, TD; Le, A; Lee, IJ; Lee, MY; Liu, W; Mallick, S; Marshall, PA; Moen, GA; Noh, Y; Peoples, SJ; Perez, A; Petros, R; Reshi, S; Salama, E; Salama, J; Sausedo, MA; Savage, BM; Tromba, L; Wagner, CE; Welch, JS; Ziller, JW	1
Fukumoto, T; Imamura, S; Itoh, T; Kubo, A; Nakamura, K; Nakano, E; Nishigori, C; Tanaka, T; Tanigawa, A	1
Assaf, C; Querfeld, C; Scandurra, M; Scarisbrick, JJ; Turini, M	1
Elsea, D; Lilley, C; Lisano, J; Liu, J; Savage, KJ; Yu, KS	1
Applegate, MT; Haddad, D; Jurutka, PW; Khamisi, M; Livingston, S; Marshall, PA; Reshi, S; Ron, E; Sabir, Z; Sausedo, M; Staniszewski, LJP; Wagner, CE; Warda, A	1
Chen, PL; Malachowski, SJ; Seminario-Vidal, L; Sun, J	1
Kato, H; Kubo, R; Morita, A; Muramatsu, S; Nishida, E; Tateishi, C; Tsuruta, D; Yonezawa, E	1
Aiba, S; Amagai, R; Fujimura, T; Fujisawa, Y; Fukushima, S; Kambayashi, Y; Miyashita, A; Ogata, D; Sato, Y; Shimauchi, T; Tanita, K	1
Christensen, LF; Cooper, KD; Ellis, A; Kord, H; Meyerson, H; Sharma, T	1
Dreyer, S; Goh, C; Smart, C	1
Bunch, C; Jäger, M; Schmitt, J; Valipour, A; Weberschock, T; Wu, P	1
Briones, J; Espeso, M; Martín, A; Mozos, A; Novelli, S; Sánchez, JJ	1
Benoit, B; Berg, S; Clark, RA; Del Guzzo, C; Durgin, JS; Haun, PL; Inverso, J; Jariwala, NN; Kim, EJ; Lewis, DJ; Maity, A; Plastaras, JP; Rook, AH; Rosenthal, JM; Samimi, SS; Teague, JE; Villasenor-Park, J; Vittorio, C; Wysocka, M; Zhang, KK	1
Hisamoto, T; Kawana, Y; Miyagaki, T; Oka, T; Sato, S; Suga, H; Sugaya, M	1
Foss, F; Montanari, F; Reddy, N; Sethi, TK	1
Zic, JA	1
Gulekon, A; Tamer, F	1
Alpdogan, SO; Cha, J; Correia, E; Krishnasamy, S; Nikbakht, N; O'Donnell, M; Porcu, P; Sahu, J; Shi, W; Zaya, R	1
Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S	1
Einar French, L; Guertler, A; Helene Frommherz, L; Kaemmerer, T; Reinholz, M; Stadler, PC	1
Eshagh, K; Romero, LS; So, JK; Zhao, XF	1
Duvic, M; Huang, S; Lewis, DJ	1
Assaf, C; Nicolay, JP	1
Aiba, S; Fujimura, T; Furudate, S; Hidaka, T; Kambayashi, Y; Sato, Y; Tanita, K	1
Geskin, L; Malone, DC	1
Hamada, T; Iwatsuki, K; Kawai, K; Kiyohara, E; Matsushita, S; Nagatani, T; Ohtsuka, M; Saida, T; Setoyama, M; Sugaya, M; Tani, M; Tokura, Y; Tsuboi, R; Yonekura, K	1
Alfano, R; Argenziano, G; Caccavale, S; Franco, R; Jurakic Toncic, R; Panarese, I; Ronchi, A; Sica, A; Vitiello, P	1
Duvic, M; Park, KE; Ramachandran, V	1
Mark, LA; Yao, Y	1
Calderon Cabrera, C; Carrillo Cruz, E; de la Cruz Vicente, F; Espigado Tocino, I; Falantes, JF; Marín-Niebla, A; Martino Galiana, ML; Perez-Simón, JA; Prats Martín, C; Rios Herranz, E	1
Cowper, S; Girardi, M; Huang, J; Moss, J	1
Deonizio, JM; Guitart, J; Vaghani, SP	1
Chan, C; Counsell, N; Cowan, R; Gilson, D; Illidge, T; Morris, S; Patrick, P; Popova, B; Scarisbrick, J; Smith, P; Whittaker, S	1
Duvic, M; Feldman, T; Goy, A; Hernandez-Ilizaliturri, FJ; Horwitz, SM; Hymes, K; Myskowski, PL; Straus, DJ; Wegner, B	1
Dalle, S; Graeppi-Dulac, J; Orgiazzi, J; Perier-Muzet, M; Vlaeminck-Guillem, V	1
Helbig, D; Wirtz, M	1
Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S	1
González-Morán, A; Otero-Rivas, MM; Rodríguez-Prieto, MÁ; Sánchez-Sambucety, P	1
Fabri, M; Felcht, M; Herling, M; Klemke, CD; Mrotzek, C; Schlaak, M; Schrader, A; Sommer, A	1
Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J	1
Huen, AO; Kim, EJ	1
Chiacchio, R; Errichetti, E; Piccirillo, A	1
Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S	1
Craig, FE; Grandinetti, LM; Ho, J; Jedrych, J; Johnson, WT; Leeman-Neill, RJ; Patel, P	1
Broussard, KC; Patrawala, SA; Wang, L; Zic, JA	1
Bagot, M; Bouaziz, JD; Haber, R; Jachiet, M; Laly, P; Ram-Wolff, C; Rivet, J	1
Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O	1
Bansal, A; Benoit, B; Cha, XY; Fakharzadeh, SS; Kim, EJ; Lin, JH; Nasta, S; Richardson, SK; Rook, AH; Seykora, J; Wysocka, M; Zafar, S	1
Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A	1
Arulogun, S; Eaton, E; Gambell, P; Lade, S; McCormack, C; Prince, HM; Ryan, G	1
Fleischer, AB; Kannangara, AP; Levitan, D	1
Apraiz, A; Asumendi, A; Boyano, MD; Díaz-Pérez, JL; Izu, R; Nieto-Rementería, N; Pérez-Yarza, G	1
Horwitz, SM	1
Goerdt, S; Klemke, CD	1
Ardizzoni, A; Di Nuzzo, S; Musolino, A; Panebianco, M; Santini, M; Zendri, E	1
Abbott, RA; Bashir, SJ; Hung, T; Morris, SL; Russell-Jones, R; Scarisbrick, JJ; Whittaker, SJ	1
Tronnier, M	1
Catherwood, M; Morris, TC; Pettengell, R; Sheehy, O	1
D'Acunto, C; Gurioli, C; Neri, I	1
Amitay-Laish, I; David, M; Hodak, E	1
Ballanger, F; Brocard, A; Dréno, B; Khammari, A; Knol, AC; Nguyen, JM; Quéreux, G	2
Anand, D; Gormley, RH; Hess, SD; Junkins-Hopkins, J; Kim, EJ; Rook, AH	1
Climent, J; Estrach, T; Gallardo, F; Garcia-Muret, P; Muniesa, C; Pujol, RM; Servitje, O	1
Ballanger, F; Dréno, B; Khammari, A; Nguyen, JM	1
Bair, SM; Cherpelis, BS; Glass, LF; Marquez, C; Smithberger, E	1
Farley-Loftus, R; Latkowski, JA; Mandal, R	1
Krohn, K; Ranki, A; Sipilä, L; Väkevä, L	1
Battistella, M; Sassolas, B	1
Cutlan, J; Duvic, M; Holcomb, M	1
Chemnitz, J; Kurschat, P; Scheid, C; Schlaak, M; Shimabukuro-Vornhagen, A; Stadler, R; Theurich, S; von Bergwelt-Baildon, M	1
Alves, R; Fernandes, I; Lima, M; Oliveira, A; Selores, M	1
Alvarado, CS; Busam, KJ; Hale, GA; Horwitz, S; Jaffe, ES; Kim, YH; Mehta, N; Myskowski, P; Pulitzer, M; Wayne, AS; Zwerner, J	1
Altiner, A; Berger, E; Chu, J; Latkowski, JA; Patel, R; Sanders, S	1
Chu, J; Marmon, S; Meehan, S; Patel, R; Pomeranz, MK	1
Bagot, M; Bensussan, A; Caudron, A; Marie-Cardine, A	1
Hahtola, S; Ranki, A; Väkevä, L	1
Hall, AG; Marshall, GD; Morris, AE	1
Cheeley, J; DeLong, LK; Parker, SR; Sahn, RE	1
Ahmed, Z; Piguet, V	1
Dummer, R; Gellrich, S; Hasan, B; Karrasch, M; Knobler, R; Meulemans, B; Ortiz, P; Ranki, A; Stadler, R; Whittaker, S	1
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS	1
Assaf, C; Becker, JC; Dummer, R; Duvic, M; Grazia Bernengo, M; Lebbé, C; Marshood, M; Ortiz Romero, P; Poulalhon, N; Prince, HM; Squier, M; Tai, F; Williams, D	1
Alterini, R; Canafoglia, L; Delfino, C; Goteri, G; Grandi, V; Pileri, A; Pimpinelli, N; Quaglino, P; Rupoli, S	1
Keun, YK; Sangueza, O; Woodruff, R	1
Apisarnthanarax, N; Breuer-Mcham, J; Duvic, M; Talpur, R; Ward, S	1
French, LE; Junkins-Hopkins, JM; Lehrer, MS; Rook, AH; Shapiro, M; Vittorio, CC	1
Budgin, JB; Everitts, S; Junkins-Hopkins, JM; McGinnis, KS; Richardson, SK; Rook, AH; Vittorio, CC; Wysocka, M	1
Duvic, M; Lain, T; Talpur, R	1
Sherman, SI	1
Apisarnthanarax, N; Duvic, M; Ha, CS	1
Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC	1
Lebwohl, M; Stern, DK	1
Martin, AG	1
Duvic, M; Hanson, M; Hill, A	1
Crowley, CA; Heald, P; Martin, AG; Mehlmauer, M; Reich, SD; Yocum, RC	1
Beyeler, M; Dummer, R	1
Crawford, G; Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC	1
Farol, LT; Hymes, KB	1
Mehlmauer, MA	1
Andreeff, M; Duvic, M; Konopleva, M; Ni, X; Zhang, C	1
Foss, F	1
Whitmore, SE	1
Bouwhuis, SA; el-Azhary, RA	1
Benoit, B; Budgin, JB; Newton, SB; Richardson, SK; Rook, AH; Wysocka, M; Zaki, MH	1
Demierre, MF; DiVenuti, G; Foss, F	1
Bouwhuis, SA; Davis, MD; el-Azhary, RA; Gibson, LE; Kist, JM; Knudsen, JM; McEvoy, MT; Pittelkow, MR	1
Biagi, J; Brennand, S; Kennedy, G; McCormack, CJ; Prince, HM; Seymour, JF; Sutton, VR; Trapani, JA; Westerman, D	1
Coors, EA; Von den Driesch, P	1
Junkins-Hopkins, JM; Kim, EJ; McGinnis, KS; Newton, S; Rook, AH; Ubriani, R; Vittorio, CC; Wysocka, M	1
Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W	1
Altmeyer, P; Kreuter, A	1
Alencar, AJ; Apisarnthanarax, N; Duvic, M; Herne, KL; Jones, DM; Talpur, R; Yang, Y	1
Acebo, E; Díaz-Pérez, JL; Eguino, P; Izu, R; Lasa, O	1
Guitart, J	1
Cerroni, L; French, LE; Kerl, K; Prins, C	1
Altmeyer, P; Gambichler, T; Kreuter, A	1
Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S	2
Arrue, I; Fernández-Herrera, J; García-Romero, D; Ortiz-Romero, PL; Polo, I; Rosales, B; Ruiz, D; Sánchez-Largo, ME; Sanz, H; Valverde, R; Vanaclocha, F	1
García-Arpa, M; González-García, J; Rodríguez-Vázquez, M	1
Bradley, B; Parker, SR	1
Bertsch, HP; Mitteldorf, C; Neumann, C; Stadler, R	1
Demierre, MF; Duvic, M; Horwitz, S; Kuzel, T; Myskowski, P; Steckel, S; Straus, DJ	1
Ardigò, M; Berardesca, E; Cota, C; Marulli, GC; Mastroianni, A	1
Hymes, KB	1
Stadler, R	1
Demierre, MF; Ferzli, P; Miller, D	1
Benoit, BM; Newton, SB; Rook, AH; Wysocka, M; Yoon, JS	1
Assaf, C; Bagot, M; Dummer, R; Gniadecki, R; Hauschild, A; Knobler, R; Ranki, A; Stadler, R; Whittaker, S	1
Scheinfeld, N	1
Beylot-Barry, M	1
Bagazgoitia, L; Harto, A; Jaén, P; Muñoz, E; Pérez-Carmona, L; Ríos, L	1
Avilés Pérez, MD; de Argila Fernández-Durán, D; Díaz Pérez de Madrid, J; Luna López, V; Rodríguez Nevado, I	1
Aldaoud, A	1
Bachelez, H	1
Bagot, M	1
Coors, E	1
Gniadecki, R; Kamstrup, M	1
Dalle, S; Thomas, L	1
Otremba, B	1
Ranki, A	1
Scharffetter-Kochanek, K; Staib, G	1
Stein, A	1
Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W	1
Asteria, C	1
Bailly, C; Formstecher, P; Lansiaux, A	1
Bell, TJ	1
Baker, C; Davison, J; McCormack, C; Prince, HM; Rotstein, H; Ryan, G; Yocum, R	1
Crowley, CA; Duvic, M; Kim, Y; Martin, AG; Olsen, E; Wood, GS; Yocum, RC	1
LeMaistre, CF	1
Heald, P	1
Duvic, M	1
French, LE; Junkins-Hopkins, JM; Rook, AH; Shapiro, M; Vittorio, CC	1
Breneman, D; Duvic, M; Kuzel, T; Stevens, VJ; Truglia, J; Yocum, R	1
Kim, YH; Liu, HL	1
Duvic, M; Hazarika, P; Ni, X; Weidner, DA; Zhang, C	1

Reviews

38 review(s) available for bexarotene and Skin Neoplasms

Article	Year
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2022, Volume: 40, Issue:5 Topics: Adult; Antibodies, Monoclonal, Humanized; Bexarotene; Cost-Benefit Analysis; Humans; Mycosis Fungoides; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sezary Syndrome; Skin Neoplasms; State Medicine; Technology; Technology Assessment, Biomedical; Vorinostat	2022
Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis. Dermatologic therapy, 2022, Volume: 35, Issue:5 Topics: Adult; Bexarotene; Female; Humans; Male; Mycosis Fungoides; Phototherapy; Prospective Studies; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2022
Diagnosis and Management of Cutaneous B-Cell Lymphomas. Dermatologic clinics, 2019, Volume: 37, Issue:4 Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Borrelia burgdorferi; Cyclophosphamide; Cytoreduction Surgical Procedures; Dermatologic Surgical Procedures; Disease Management; Doxorubicin; Humans; Injections, Intralesional; Lyme Disease; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Polyethylene Glycols; Prednisone; Rituximab; Skin Neoplasms; Vincristine	2019
Interventions for mycosis fungoides. The Cochrane database of systematic reviews, 2020, 07-07, Volume: 7 Topics: Acitretin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Humans; Immunologic Factors; Interferon-alpha; Mycosis Fungoides; Neoplasm Staging; Photochemotherapy; Photopheresis; PUVA Therapy; Randomized Controlled Trials as Topic; Skin Neoplasms	2020
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Male; Mycosis Fungoides; Neoplasm Staging; Neoplastic Stem Cells; Photopheresis; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Signal Transduction; Skin Neoplasms; T-Lymphocyte Subsets	2021
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma. The Medical clinics of North America, 2021, Volume: 105, Issue:4 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms	2021
[Treatment of mycosis fungoides and Sézary syndrome]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017, Volume: 68, Issue:9 Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization	2017
Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. European journal of endocrinology, 2014, Volume: 170, Issue:6 Topics: Aged; Antineoplastic Agents; Bexarotene; Endocrine System Diseases; Female; Gene Expression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Thyroid Gland; Thyrotropin; Thyrotropin, beta Subunit	2014
Systematic review of combination therapies for mycosis fungoides. Cancer treatment reviews, 2014, Volume: 40, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2014
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatologic clinics, 2015, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Humans; Hyperlipidemias; Hypothyroidism; Immunologic Factors; Interferons; Mycosis Fungoides; PUVA Therapy; Retinoids; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2015
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2008
Novel therapies for cutaneous T-cell lymphomas. Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 5 Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2008
Molecular biology and targeted therapy of cutaneous T-cell lymphomas. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2008, Volume: 143, Issue:6 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cytokines; Dendritic Cells; Diphtheria Toxin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interleukin-2; Keratinocytes; Lymphoma, T-Cell; Macrophages; Mast Cells; Membrane Glycoproteins; NF-kappa B; Receptors, Chemokine; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2008
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. Journal of the American Academy of Dermatology, 2010, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Bexarotene; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Humans; Lymphoma, T-Cell, Cutaneous; Male; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2010
Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:7 Topics: Acitretin; Anticarcinogenic Agents; Bexarotene; Humans; Risk; Skin Neoplasms; Tetrahydronaphthalenes	2010
Mycosis fungoides stage IB progressing to cutaneous tumors. Dermatology online journal, 2011, Oct-15, Volume: 17, Issue:10 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Black or African American; Disease Progression; Female; Humans; Interferon-alpha; Methotrexate; Mycosis Fungoides; Skin Neoplasms; Skin Pigmentation; Tetrahydronaphthalenes; Ultraviolet Therapy	2011
Recurrent localized primary cutaneous marginal-zone B cell lymphoma. Dermatology online journal, 2011, Oct-15, Volume: 17, Issue:10 Topics: Adult; Antigens, CD20; Arm; Bexarotene; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Humans; Ki-67 Antigen; Lymphoma, B-Cell, Marginal Zone; Male; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Tetrahydronaphthalenes	2011
[New developments in Sézary syndrome]. Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Combined Modality Therapy; Diphtheria Toxin; Disease Models, Animal; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Interleukin-2; Mice; Mice, SCID; Molecular Targeted Therapy; Photopheresis; PUVA Therapy; Receptors, KIR3DL2; Recombinant Fusion Proteins; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Therapies, Investigational	2012
Not all that itches is urticaria. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:1 Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Bexarotene; Biopsy, Needle; Black or African American; Diagnosis, Differential; Education, Medical, Continuing; Eosinophilia; Female; Humans; Ki-1 Antigen; Methotrexate; Middle Aged; Mycosis Fungoides; Prednisone; Pruritus; Skin Neoplasms; Tetrahydronaphthalenes; Urticaria	2012
Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Advances in dermatology, 2002, Volume: 18 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cytokines; Diphtheria Toxin; Humans; Immunotherapy; Interferon Type I; Interferon-gamma; Interleukin-12; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Photopheresis; Recombinant Fusion Proteins; Recombinant Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2002
Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clinical lymphoma, 2003, Volume: 3, Issue:4 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin	2003
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Archives of dermatology, 2003, Volume: 139, Issue:6 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Female; Ficusin; Humans; Male; Middle Aged; Photosensitizing Agents; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2003
Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. Journal of drugs in dermatology : JDD, 2003, Volume: 2, Issue:2 Topics: Administration, Topical; Bexarotene; Gels; Humans; Lymphoma, T-Cell, Cutaneous; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2003
[Standard and experimental therapy of cutaneous T-cell lymphoma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:12 Topics: Adrenal Cortex Hormones; Aminoquinolines; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell; Methotrexate; Photopheresis; Prednisone; PUVA Therapy; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, High-Energy; Recombinant Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine	2003
Bexarotene: a clinical review. Expert review of anticancer therapy, 2004, Volume: 4, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Humans; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Neoplasms; Skin Neoplasms; Tetrahydronaphthalenes	2004
Mycosis fungoides and the Sézary syndrome. Current opinion in oncology, 2004, Volume: 16, Issue:5 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; Neoplasm Staging; Prognosis; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2004
Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A. The British journal of dermatology, 2005, Volume: 152, Issue:6 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Male; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2005
Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Seminars in oncology, 2006, Volume: 33, Issue:1 Suppl 3 Topics: Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Humans; Lymphoma, T-Cell, Cutaneous; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. The British journal of dermatology, 2006, Volume: 155, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2006
Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatology nursing, 2006, Volume: 18, Issue:6 Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antineoplastic Agents; Bexarotene; Biopsy; Cost of Illness; Diphtheria Toxin; Foundations; Humans; Hydroxamic Acids; Interferons; Interleukin-2; Mechlorethamine; Mycosis Fungoides; Neoplasm Staging; Photopheresis; Phototherapy; Physical Examination; Radiotherapy; Recombinant Fusion Proteins; Retinoids; Self-Help Groups; Skin Care; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2006
Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl 1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cytokines; Diphtheria Toxin; Humans; Immunologic Factors; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Neoplasm Staging; Purines; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2007
Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Combined Modality Therapy; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Neoplasm Staging; Photopheresis; PUVA Therapy; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2007
The optimal use of bexarotene in cutaneous T-cell lymphoma. The British journal of dermatology, 2007, Volume: 157, Issue:3 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; PUVA Therapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:16 Topics: Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Staging; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approval; Humans; Hydroxamic Acids; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2007
Treatment with retinoid X receptorgamma-selective ligand (bexarotene) may cause iatrogenic central hypothyroidism. European journal of endocrinology, 2000, Volume: 142, Issue:4 Topics: Animals; Bexarotene; Humans; Hypothyroidism; Iatrogenic Disease; Lymphoma, T-Cell; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2000
The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Bexarotene; Humans; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes	2000
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Diphtheria Toxin; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Immunotoxins; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2000

Trials

15 trial(s) available for bexarotene and Skin Neoplasms

Article	Year
Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial. Acta dermato-venereologica, 2023, 02-07, Volume: 103 Topics: Bexarotene; Humans; Mechlorethamine; Phototherapy; Skin Neoplasms	2023
Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. The Journal of dermatology, 2020, Volume: 47, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bexarotene; Disease Progression; Female; Heart Failure; Humans; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; PUVA Therapy; Sepsis; Severity of Illness Index; Skin Neoplasms; Treatment Outcome	2020
Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201). The Journal of dermatology, 2019, Volume: 46, Issue:7 Topics: Adult; Antineoplastic Agents; Bexarotene; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Japan; Leukopenia; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Mycosis Fungoides; Neoplasm Staging; Neutropenia; Skin Neoplasms; Time Factors; Young Adult	2019
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United Kingdom	2013
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Disease-Free Survival; Doxorubicin; Female; Humans; Injections; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Polyethylene Glycols; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2014
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056 The British journal of dermatology, 2012, Volume: 167, Issue:3 Topics: Adolescent; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Early Termination of Clinical Trials; Humans; Infant; Methoxsalen; Middle Aged; Mycosis Fungoides; Photosensitizing Agents; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult	2012
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Disease Progression; Disease-Free Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Mycosis Fungoides; Panobinostat; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2013
Long-term control of mycosis fungoides of the hands with topical bexarotene. International journal of dermatology, 2003, Volume: 42, Issue:3 Topics: Administration, Topical; Adult; Anticarcinogenic Agents; Bexarotene; Hand; Humans; Male; Mycosis Fungoides; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2003
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:5 Topics: Administration, Topical; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2003
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood, 2005, Jul-15, Volume: 106, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Drug Tolerance; Female; Humans; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Fusion Proteins; Recurrence; Skin Neoplasms; Tetrahydronaphthalenes; Up-Regulation	2005
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer, 2007, May-01, Volume: 109, Issue:9 Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. The Australasian journal of dermatology, 2001, Volume: 42, Issue:2 Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Australia; Bexarotene; Capsules; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gels; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Prognosis; Remission Induction; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2001
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of dermatology, 2001, Volume: 137, Issue:5 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Capsules; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Skin Neoplasms; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome	2001
The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Bexarotene; Humans; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes	2000
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Archives of dermatology, 2002, Volume: 138, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Gels; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Safety; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2002

Other Studies

117 other study(ies) available for bexarotene and Skin Neoplasms

Article	Year
Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers. Journal of medicinal chemistry, 2022, 11-10, Volume: 65, Issue:21 Topics: Humans; Inflammation; Ligands; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes; Tretinoin; Triglycerides	2022
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:3 Topics: Bexarotene; Electrons; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome	2022
Complete remission with bexarotene gel in unilesional folliculotropic mycosis fungoides located on the scalp. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Bexarotene; Humans; Mycosis Fungoides; Remission Induction; Scalp; Skin Neoplasms	2022
The oral cavity and gastric involvement in mycosis fungoides while on systemic bexarotene therapy: A rare case report. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mouth; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2022
Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. Acta dermato-venereologica, 2022, 07-07, Volume: 102 Topics: Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; T-Lymphocytes	2022
Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis. Scientific reports, 2022, 07-01, Volume: 12, Issue:1 Topics: Bexarotene; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Death; Female; Humans; Ovarian Neoplasms; Pyroptosis; Skin Neoplasms	2022
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Humans; Integrin alphaVbeta3; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2022
Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. The British journal of dermatology, 2022, Volume: 187, Issue:6 Topics: Acitretin; Anticarcinogenic Agents; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplasms; Tetrahydronaphthalenes	2022
Successful treatment of CD8+ syringotropic mycosis fungoides with bexarotene and local radiotherapy. Dermatologic therapy, 2022, Volume: 35, Issue:11 Topics: Bexarotene; CD8-Positive T-Lymphocytes; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2022
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:21 Topics: Adult; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms	2022
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene. International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24 Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides	2022
CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy. The Journal of dermatology, 2023, Volume: 50, Issue:7 Topics: Bexarotene; CD8-Positive T-Lymphocytes; Electrons; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms	2023
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Advances in therapy, 2023, Volume: 40, Issue:5 Topics: Bexarotene; Brentuximab Vedotin; Canada; Cost-Benefit Analysis; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Methotrexate; Neoplasm Recurrence, Local; Physicians; Skin Neoplasms	2023
Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas. Cells, 2023, Nov-04, Volume: 12, Issue:21 Topics: Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes	2023
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. The Journal of dermatology, 2020, Volume: 47, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Chemoradiotherapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Severity of Illness Index; Skin Neoplasms; Ultraviolet Therapy	2020
CD30 Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:2 Topics: Aged; Bexarotene; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Treatment Outcome; Vorinostat	2021
Lichen planopilaris in a patient treated with bexarotene for lymphomatoid papulosis. Cutis, 2020, Volume: 105, Issue:4 Topics: Bexarotene; Hodgkin Disease; Humans; Lichen Planus; Lymphomatoid Papulosis; Skin Neoplasms	2020
Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units. European journal of dermatology : EJD, 2020, Aug-01, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Palliative Care; Prednisone; Referral and Consultation; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Spain; Survival Analysis; Transplantation, Homologous; Vincristine	2020
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis. JAMA dermatology, 2021, 01-01, Volume: 157, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Combined Modality Therapy; Electrons; Humans; Immunotherapy; Interferon-gamma; Male; Middle Aged; Photopheresis; Radiotherapy Dosage; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Treatment Outcome	2021
A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab. Dermatologic therapy, 2021, Volume: 34, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2021
Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2021, Volume: 30, Issue:6 Topics: Anticarcinogenic Agents; Bexarotene; Biomarkers; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2021
Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study. Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:6 Topics: Bexarotene; Brentuximab Vedotin; Cell Transformation, Neoplastic; Humans; Mycosis Fungoides; Prognosis; Retrospective Studies; Skin Neoplasms	2022
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. Endocrine journal, 2022, Jan-28, Volume: 69, Issue:1 Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplasms; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine	2022
Alitretinoin in the treatment of cutaneous T-cell lymphoma. Cancer medicine, 2021, Volume: 10, Issue:20 Topics: Adult; Aged; Alitretinoin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Sezary Syndrome; Skin Neoplasms	2021
Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient. Cutis, 2017, Volume: 99, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; CD4-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell, Cutaneous; Lymphopenia; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2017
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatologic therapy, 2017, Volume: 30, Issue:5 Topics: Administration, Oral; Anticarcinogenic Agents; Bexarotene; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Treatment Outcome	2017
Successful control of phototherapy-resistant lymphomatoid papulosis with oral bexarotene. The Journal of dermatology, 2018, Volume: 45, Issue:2 Topics: Antineoplastic Agents; Bexarotene; Female; Humans; Lymphomatoid Papulosis; Middle Aged; Phototherapy; Skin; Skin Neoplasms; Treatment Outcome	2018
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. The Journal of dermatological treatment, 2018, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Methotrexate; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2018
Dermoscopic characterization of folliculotropic mycosis fungoides selectively localized on trunk and limbs. International journal of dermatology, 2019, Volume: 58, Issue:10 Topics: Bexarotene; Biopsy; Dermoscopy; Diagnosis, Differential; Extremities; Humans; Lymphoma; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin; Skin Neoplasms; Torso; Treatment Outcome	2019
Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. International journal of dermatology, 2019, Volume: 58, Issue:11 Topics: Administration, Cutaneous; Adult; Antineoplastic Agents; Bexarotene; Hand; Humans; Male; Mycosis Fungoides; Skin Neoplasms; Time Factors; Treatment Outcome	2019
Woringer-Kolopp disease mimicking foot dermatitis. Cutis, 2012, Volume: 90, Issue:6 Topics: Aged; Anticarcinogenic Agents; Bexarotene; CD3 Complex; Dermatologic Agents; Diagnosis, Differential; Foot Dermatoses; Humans; Male; Pagetoid Reticulosis; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes; Urea	2012
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome. British journal of haematology, 2013, Volume: 162, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Humans; Mycosis Fungoides; Pentostatin; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:4 Topics: Administration, Oral; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Ficusin; Follow-Up Studies; Humans; Lasers, Excimer; Male; Middle Aged; Mycosis Fungoides; Photosensitizing Agents; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2013
Topical bexarotene for psoralen plus ultraviolet A-induced photodamage. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:2 Topics: Administration, Topical; Bexarotene; Follow-Up Studies; Humans; Male; Middle Aged; Mycosis Fungoides; Photosensitivity Disorders; PUVA Therapy; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
[Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014, Volume: 65, Issue:4 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Hodgkin Disease; Humans; Male; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2014
Papuloerythroderma of Ofuji associated with CD3,(+) CD4,(+) and CD8(-) cutaneous T-cell lymphoma and monoclonal gammopathy of undetermined significance. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:5 Topics: Bexarotene; CD3 Complex; CD4 Antigens; Eosinophilia; Folliculitis; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; PUVA Therapy; Remission Induction; Skin Diseases, Vesiculobullous; Skin Neoplasms; T-Lymphocyte Subsets; Tetrahydronaphthalenes	2015
Vitamin D controls apoptosis and proliferation of cutaneous T-cell lymphoma cells. Experimental dermatology, 2015, Volume: 24, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Bexarotene; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Mycosis Fungoides; Receptors, Calcitriol; Retinoid X Receptors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Vitamin D; Vitamin D Deficiency	2015
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:8 Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2015
Folliculotropic mycosis fungoides presenting as non-inflammatory scarring scalp alopecia associated with comedo-like lesions. International journal of dermatology, 2016, Volume: 55, Issue:1 Topics: Alopecia; Bexarotene; Biopsy, Needle; Cicatrix; Diagnosis, Differential; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2016
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. Medicina clinica, 2016, Feb-05, Volume: 146, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cholesterol, HDL; Combined Modality Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2016
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment. The American Journal of dermatopathology, 2016, Volume: 38, Issue:11 Topics: Aged; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Depsipeptides; Disease Progression; Drug Substitution; Fatal Outcome; Humans; Immunohistochemistry; Immunophenotyping; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Metastasis; Phenotype; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2016
Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome. Dermatology online journal, 2016, May-15, Volume: 22, Issue:5 Topics: Age Factors; Aged; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cell Transformation, Neoplastic; Disease Progression; Female; Furocoumarins; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prognosis; Radiotherapy; Retrospective Studies; Skin; Skin Neoplasms; Tertiary Care Centers; Tetrahydronaphthalenes; Ultraviolet Therapy	2016
Photo-sensitive mycosis fungoides: a new variant? European journal of dermatology : EJD, 2017, 04-01, Volume: 27, Issue:2 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Depsipeptides; Humans; Male; Middle Aged; Mycosis Fungoides; Photosensitivity Disorders; Skin Neoplasms; Tetrahydronaphthalenes	2017
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clinical and experimental dermatology, 2017, Volume: 42, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipid Metabolism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes	2017
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. Blood, 2008, Sep-15, Volume: 112, Issue:6 Topics: Bexarotene; Drug Resistance, Neoplasm; Humans; Leukemia-Lymphoma, Adult T-Cell; Lymph Nodes; Male; Middle Aged; Recurrence; Retinoid X Receptor alpha; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes	2008
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cohort Studies; Disease-Free Survival; Female; Humans; Interferon-alpha; Male; Methotrexate; Middle Aged; Photopheresis; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2008
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. The Journal of dermatological treatment, 2009, Volume: 20, Issue:3 Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Retrospective Studies; Risk Assessment; Sex Factors; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2009
Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. The British journal of dermatology, 2009, Volume: 160, Issue:3 Topics: Anticarcinogenic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bexarotene; Cell Cycle; Cell Cycle Proteins; Cell Survival; DNA-Binding Proteins; Humans; Lymphoma, T-Cell, Cutaneous; Neoplastic Stem Cells; Nuclear Proteins; Protein Serine-Threonine Kinases; Signal Transduction; Skin Neoplasms; Tetrahydronaphthalenes; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2009
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. British journal of haematology, 2009, Volume: 145, Issue:1 Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
Bexarotene therapy for mycosis fungoides and Sézary syndrome. The British journal of dermatology, 2009, Volume: 160, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Cohort Studies; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sex Factors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood. Journal of cutaneous pathology, 2009, Volume: 36, Issue:5 Topics: Adolescent; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Foreign Bodies; Giant Cells; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2009
Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. Leukemia & lymphoma, 2009, Volume: 50, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Facial Neoplasms; Female; Humans; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Neoplasm Recurrence, Local; Photopheresis; Prednisone; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine	2009
Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. The Journal of dermatological treatment, 2010, Volume: 21, Issue:1 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2010
Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:2 Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retreatment; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
About the cutaneous targets of bexarotene in CTCL patients. Experimental dermatology, 2010, Volume: 19, Issue:8 Topics: Aged; Anticarcinogenic Agents; Antigens, CD1; Apoptosis; Bexarotene; Biopsy; Case-Control Studies; Female; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Keratinocytes; Langerhans Cells; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes	2010
Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Experimental dermatology, 2010, Volume: 19, Issue:8 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; T-Lymphocytes, Regulatory; Tetrahydronaphthalenes; Transforming Growth Factor beta1	2010
Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. Journal of the American Academy of Dermatology, 2010, Volume: 62, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2010
Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Phototherapy; Retrospective Studies; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes; Treatment Outcome	2010
Poikilodermatous mycosis fungoides. Dermatology online journal, 2010, Nov-15, Volume: 16, Issue:11 Topics: Acitretin; Antineoplastic Agents; Bexarotene; Female; Humans; Hydroxamic Acids; Hypopigmentation; Immunophenotyping; Interferon-alpha; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy; Vorinostat	2010
Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. Acta dermato-venereologica, 2011, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Cells, Cultured; Chromosomes, Human, Pair 12; Finland; Gene Deletion; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lymphoma, T-Cell, Cutaneous; Membrane Proteins; Nerve Tissue Proteins; Patient Selection; Pharmacogenetics; Precision Medicine; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Tetraploidy; Time Factors; Treatment Outcome	2011
[Therapeutic perspectives of cutaneous T-cell lymphoma]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 2 Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Interferons; Lymphoma, T-Cell, Cutaneous; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2011
Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. International journal of dermatology, 2012, Volume: 51, Issue:10 Topics: Aged; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Electrons; Erythema; Humans; Male; Mechlorethamine; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Triamcinolone	2012
Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transplant immunology, 2011, Volume: 25, Issue:2-3 Topics: Adult; Bexarotene; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphocyte Transfusion; Lymphoma, T-Cell, Cutaneous; Male; Photopheresis; PUVA Therapy; Recurrence; Skin Neoplasms; Tetrahydronaphthalenes	2011
Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene. Leukemia research, 2011, Volume: 35, Issue:11 Topics: Anticarcinogenic Agents; Bexarotene; Female; Humans; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2011
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Diabetes Mellitus, Type 1; Disease-Free Survival; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Panniculitis; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult	2012
Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta dermato-venereologica, 2012, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticarcinogenic Agents; Aspartate Aminotransferases; Bexarotene; Combined Modality Therapy; Finland; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Liver; Lymphoma, T-Cell, Cutaneous; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Skin Neoplasms; Tetrahydronaphthalenes	2012
Acitretin for the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:2 Topics: Acitretin; Adult; Aged; Aged, 80 and over; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Combining rexinoids with psoralen-ultraviolet A sheds light on the management of mycosis fungoides. The British journal of dermatology, 2012, Volume: 167, Issue:3 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2012
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. The British journal of dermatology, 2013, Volume: 168, Issue:1 Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, HDL; Clinical Protocols; Drug Administration Schedule; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver Function Tests; Lymphoma, T-Cell, Cutaneous; Musculoskeletal Pain; Pancreatitis; Pregnancy; Pregnancy Complications; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin; Thyroxine	2013
Combination treatment in CTCL: the current role of bexarotene. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2012, Volume: 147, Issue:6 Topics: Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Humans; Italy; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes	2012
Response of CD30+ large cell lymphoma of skin to bexarotene. Leukemia & lymphoma, 2002, Volume: 43, Issue:5 Topics: Aged; Aged, 80 and over; Bexarotene; Female; Humans; Ki-1 Antigen; Lymphoma, Large B-Cell, Diffuse; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2002
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:5 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Dermatitis, Exfoliative; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypothyroidism; Middle Aged; Mycosis Fungoides; Photopheresis; Prospective Studies; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2002
Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:6 Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Follow-Up Studies; Humans; Immunohistochemistry; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy	2002
Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. American journal of clinical dermatology, 2003, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Bexarotene; Cell Transformation, Neoplastic; Chemotherapy, Adjuvant; Female; Humans; Mucinosis, Follicular; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2003
Treatment of mycosis fungoides with oral bexarotene combined with PUVA. Journal of drugs in dermatology : JDD, 2002, Volume: 1, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Female; Humans; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2002
Bexarotene reverses alopecia in cutaneous T-cell lymphoma. The British journal of dermatology, 2003, Volume: 149, Issue:1 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2003
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Drug Synergism; Drug Therapy, Combination; Humans; Interferon-alpha; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2004
Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene. Cutis, 2004, Volume: 73, Issue:6 Topics: Administration, Oral; Aged; Anticarcinogenic Agents; Bexarotene; Humans; Male; Mycosis Fungoides; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes	2004
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. The Journal of investigative dermatology, 2004, Volume: 123, Issue:2 Topics: Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Immunologic Factors; Ligands; Lymphocytes; Mycosis Fungoides; Nitric Oxide; Oleanolic Acid; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Transcription Factors	2004
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:3 Topics: Antineoplastic Agents; Bexarotene; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lymphocyte Activation; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes	2004
Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization. International journal of dermatology, 2005, Volume: 44, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Bexarotene; Dermatitis, Exfoliative; Erythema; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Pruritus; Retinoid X Receptors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2005
Biological effects of bexarotene in cutaneous T-cell lymphoma. Archives of dermatology, 2005, Volume: 141, Issue:3 Topics: Apoptosis; Bexarotene; Case-Control Studies; Cytokines; Drug Synergism; Female; Flow Cytometry; Humans; Interferon-alpha; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Male; Reference Values; Risk Factors; Sensitivity and Specificity; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Tumor Cells, Cultured	2005
Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2005
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy. The British journal of dermatology, 2005, Volume: 152, Issue:6 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Apoptosis; Bexarotene; Female; Humans; In Situ Nick-End Labeling; Male; Middle Aged; Neoplastic Cells, Circulating; Sezary Syndrome; Skin Neoplasms; Staining and Labeling; Tetrahydronaphthalenes; Tumor Cells, Cultured	2005
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Archives of dermatology, 2005, Volume: 141, Issue:9 Topics: Administration, Oral; Bexarotene; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Photopheresis; Recombinant Proteins; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2005
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:10 Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine	2003
Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome. Journal of the American Academy of Dermatology, 2005, Volume: 53, Issue:6 Topics: Aged; Bexarotene; CD8-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell; Male; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2005
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. The Journal of investigative dermatology, 2006, Volume: 126, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Female; Humans; Interleukin-2; Ki-1 Antigen; L-Lactate Dehydrogenase; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Fusion Proteins; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2006
[Treatment of cutaneous T-cell lymphomas with bexarotene]. Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:10 Topics: Adult; Aged; Algorithms; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes	2005
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. The British journal of dermatology, 2006, Volume: 154, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Fatal Outcome; Humans; Interleukin-2; Killer Cells, Natural; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2006
Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma. Acta dermato-venereologica, 2006, Volume: 86, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Female; Humans; Interferons; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Neoplasm Metastasis; Skin Neoplasms; Tetrahydronaphthalenes	2006
[Treatment of mycosis fungoides with PUVA and bexarotene]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:5 Topics: Adult; Aged; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2006
Juvenile mycosis fungoides treated with bexarotene and PUVA. International journal of dermatology, 2007, Volume: 46, Issue:1 Topics: Adolescent; Anticarcinogenic Agents; Bexarotene; Biopsy; Humans; Male; Mycosis Fungoides; Neoplasm Staging; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2007
Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene. The British journal of dermatology, 2007, Volume: 156, Issue:3 Topics: Adolescent; Antineoplastic Agents; Bexarotene; Female; Follow-Up Studies; Humans; Lymphoma, Large-Cell, Anaplastic; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2007
Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:2 Topics: Aged; Bexarotene; Disease-Free Survival; Drug Therapy, Combination; Humans; Interferon-alpha; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Remission Induction; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2007
Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Archives of dermatology, 2007, Volume: 143, Issue:5 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Health Status; Health Status Indicators; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Photopheresis; Pilot Projects; Quality of Life; Skin Neoplasms; Tetrahydronaphthalenes	2007
Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome. Archives of dermatology, 2007, Volume: 143, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bexarotene; CD4-Positive T-Lymphocytes; Cell Culture Techniques; Drug Resistance, Neoplasm; Humans; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Tretinoin	2007
[Bexarotene: targretin]. Annales de dermatologie et de venereologie, 2007, Volume: 134, Issue:12 Topics: Antineoplastic Agents; Bexarotene; Humans; Skin Neoplasms; Tetrahydronaphthalenes	2007
Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene. Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:3 Topics: Anticarcinogenic Agents; Bexarotene; Dermatitis, Exfoliative; Female; Humans; Keratinocytes; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2008
[Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders]. Anales de medicina interna (Madrid, Spain : 1984), 2007, Volume: 24, Issue:12 Topics: Anticarcinogenic Agents; Bexarotene; Dyslipidemias; Female; Humans; Hypothyroidism; Ligands; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes	2007
Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Antineoplastic Agents; Bexarotene; Humans; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2008
Bexarotene monotherapy for patients with advanced stage mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes	2008
Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunologic Factors; Interferon-alpha; Methotrexate; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene monotherapy for epidermotropic CD8+ CTCL. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; CD8 Antigens; Humans; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Humans; Interferons; Male; Methotrexate; Mycosis Fungoides; PUVA Therapy; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2008
Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Adult; Antineoplastic Agents; Bexarotene; Humans; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene combination therapy for patients with Sézary syndrome. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Antineoplastic Agents; Atorvastatin; Bexarotene; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2008
Bexarotene monotherapy for patients with refractory Sézary syndrome. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene monotherapy for patients with refractory early stage mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged, 80 and over; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Stroke; Tetrahydronaphthalenes	2008
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:5 Suppl 1 Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2008
[LGD1069: an antagonist to the X retinoid receptor]. Bulletin du cancer, 2000, Volume: 87, Issue:3 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cells, Cultured; Clinical Trials as Topic; Dimerization; Drug Eruptions; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Lymphoma, T-Cell; Mice; Rats; Receptors, Retinoic Acid; Retinoid X Receptors; Skin Neoplasms; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription Factors; Transcriptional Activation	2000
T-cell lymphoma products. The Nurse practitioner, 2001, Volume: 26, Issue:3 Topics: Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Interleukin-2; Lymphoma, T-Cell; Proteins; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United States; United States Food and Drug Administration	2001
Two novel therapies for the treatment of cutaneous T-cell lymphoma. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Anticarcinogenic Agents; Bexarotene; Diphtheria Toxin; Humans; Immunosuppressive Agents; Immunotoxins; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2000
Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. Journal of the American Academy of Dermatology, 2001, Volume: 45, Issue:6 Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Drug Therapy, Combination; Humans; Interferon-alpha; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms; Tetrahydronaphthalenes	2001
Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. Archives of dermatology, 2002, Volume: 138, Issue:3 Topics: Anticarcinogenic Agents; Bexarotene; Drug Approval; Gels; Humans; Lymphoma, T-Cell; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes	2002
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Annexin A5; Apoptosis; Bexarotene; Blotting, Western; Cell Cycle; Cell Survival; Chromosomal Proteins, Non-Histone; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, T-Cell, Cutaneous; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Binding; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptors; Skin Neoplasms; Survivin; Tetrahydronaphthalenes; Time Factors; Transcription Factors; Tumor Cells, Cultured	2002